Ricki Carroll, MD, MBE

Financial relationships

  • Type of financial relationship:
    Other
    Ineligible company:
    Biomarin
    Topic:
    PI for achondroplasia trial
    Date added:
    09/20/2023
    Date updated:
    09/04/2025
  • Type of financial relationship:
    Other
    Ineligible company:
    Ascendis
    Topic:
    PI for achondroplasia trial
    Date added:
    09/20/2023
    Date updated:
    09/04/2025
  • Type of financial relationship:
    Other
    Ineligible company:
    Medlife
    Topic:
    PI for RCDP natural history trial
    Date added:
    09/20/2023
    Date updated:
    09/04/2025
  • Type of financial relationship:
    Consultant
    Ineligible company:
    Actio
    Topic:
    Metatropic dysplasia
    Date added:
    09/20/2023
    Date updated:
    09/04/2025
  • Type of financial relationship:
    Consultant
    Ineligible company:
    Guidepoint
    Topic:
    Skeletal dysplasia pharmaceuticals landscape
    Date added:
    09/20/2023
    Date updated:
    09/04/2025
  • Type of financial relationship:
    Other
    Ineligible company:
    Ultragenyx
    Topic:
    PI for OI trial
    Date added:
    09/20/2023
    Date updated:
    09/04/2025
  • Type of financial relationship:
    Consultant
    Ineligible company:
    BioMarin
    Topic:
    Use of voxzogo in FGFR3-opathies
    Date added:
    09/20/2024
    Date updated:
    09/04/2025
  • Type of financial relationship:
    Other
    Ineligible company:
    Tyra
    Topic:
    PI for achondroplasia clinical trial
    Date added:
    09/04/2025
    Date updated:
    09/04/2025
  • Type of financial relationship:
    Consultant
    Ineligible company:
    Ascendis
    Topic:
    Use of transcon-CNP in FGFR3-opathies
    Date added:
    09/04/2025
    Date updated:
    09/04/2025
Return to NCHDE Hospice Palliative Medicine Fellowship Didactic Series | Skeletal Dysplasia